Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Next-day Residual Effects of TS-142 (vornorexant) in Healthy Elderly Subjects
jRCT2071230009Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vornorexant in Insomnia (4 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: RMS of COP (eyes open). Started May 2023; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on jRCT2071230009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230009.